| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/20/2009 | CN100488496C Medicine for treating lung cancer |
| 05/19/2009 | US7534871 Preparation and use of carbohydrate-based bicyclic ring structures with antimicrobial and cytostatic activity |
| 05/19/2009 | US7534870 Stable pharmaceutical composition comprising erythropoietin |
| 05/19/2009 | US7534808 Indolylmaleimide derivatives |
| 05/19/2009 | US7534805 Imidazole derivatives, their preparation and their use as medicaments |
| 05/19/2009 | US7534803 Potassium and sodium channel moderators; brain disorders; strokes; multiple sclerosis |
| 05/19/2009 | US7534802 Compounds having 4-pyridylalkylthio group as substituent |
| 05/19/2009 | US7534800 pyrrolo[2,3-b]pyridine derivatives; treatment of neurodegenerative disorders related to apoptosis and/or inflammation; compound prepared by condensation, halogenation, hydrogenation, using silan protected drivatives |
| 05/19/2009 | US7534792 Pyrrolotriazine kinase inhibitors |
| 05/19/2009 | US7534785 e.g.1-{3-[5-(4-chlorophenyl)-2-oxo-6H-1,3,4-thiadiazin-3-ylmethyl]phenyl}-3-(1-methylpyrrolidin-3-ylmethyl)urea; inhibitors of tyrosine kinases, in particular Met kinase; antitumor, antiinflammatory agent |
| 05/19/2009 | US7534776 Process for preparing water-soluble phosphonooxymethyl derivatives of alcohol and phenol |
| 05/19/2009 | US7534773 reduces the expression of testosterone-repressed prostate message-2 provides therapeutic benefits in the treatment of cancer for example prostate cancer and renal cell cancer; Combined use with taxanes synergistically enhances cytotoxic chemosensitivity of androgen-independent prostate cancer |
| 05/19/2009 | US7534772 Methods for enhancing antibody-induced cell lysis and treating cancer |
| 05/19/2009 | US7534562 Tetrahydrofolate synthetase gene |
| 05/19/2009 | US7534441 Immunogenic LHRH compositions and methods relating thereto |
| 05/19/2009 | US7534436 Peptide fragments of the harp factor inhibiting angiogenesis |
| 05/19/2009 | US7534431 Targetting antibodies containing haptens, cleaning agent, and drug delivery agent; tissue-directed therapy; solid phase synthesis |
| 05/19/2009 | CA2498047C Novel imidazole compounds as transforming growth factor (tgf) inhibitors |
| 05/19/2009 | CA2468879C Substituted cyclohexane derivatives |
| 05/19/2009 | CA2458872C Human ubiquitin-conjugating enzyme |
| 05/19/2009 | CA2400784C Therapeutic product, use and formulation thereof |
| 05/19/2009 | CA2395969C Novel tetrahydropyridines, method for the preparation thereof and pharmaceutical compositions containing them |
| 05/19/2009 | CA2382580C Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders |
| 05/19/2009 | CA2382406C Substituted 2-arylbenzazole compounds and their use as antitumour agents |
| 05/19/2009 | CA2377621C Use of nitroxides in wound healing and in the prevention of photodamage |
| 05/19/2009 | CA2368059C Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| 05/19/2009 | CA2367955C Abc1 polypeptide and methods and reagents for modulating cholesterol levels |
| 05/19/2009 | CA2345724C Use of acylcarnitines as antitumour agents |
| 05/19/2009 | CA2336634C Antiviral macrocyclic compounds |
| 05/19/2009 | CA2323237C Improved radiation therapy methods |
| 05/19/2009 | CA2318029C Apo-2 ligand |
| 05/19/2009 | CA2209167C Hydroxylamine derivatives useful for enhancing the molecular chaperon production and the preparation thereof |
| 05/19/2009 | CA2163716C Verotoxin pharmaceutical compositions and medical treatments therewith |
| 05/14/2009 | WO2009062059A2 Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
| 05/14/2009 | WO2009062054A1 Uses of anti-cd40 antibodies |
| 05/14/2009 | WO2009061996A2 Antibodies that bind human dendritic and epithelial cell 205 (dec-205) |
| 05/14/2009 | WO2009061830A1 Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor |
| 05/14/2009 | WO2009061807A2 Activin receptor-like kinase-i antagonist compositions and methods of use |
| 05/14/2009 | WO2009061781A1 Novel modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors |
| 05/14/2009 | WO2009061597A1 Compounds for inhibiting ksp kinesin activity |
| 05/14/2009 | WO2009061596A1 Compounds for inhibiting ksp kinesin activity |
| 05/14/2009 | WO2009061595A1 Compounds for inhibiting ksp kinesin activity |
| 05/14/2009 | WO2009061587A1 Corticosteroids to treat epothilone or epothilone derivative induced diarrhea |
| 05/14/2009 | WO2009061456A2 Ultrasmall superparamagnetic iron oxide nanoparticles and uses thereof |
| 05/14/2009 | WO2009061446A1 Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease |
| 05/14/2009 | WO2009061373A1 Combination therapy with organic arsenicals |
| 05/14/2009 | WO2009060982A1 Cancer cell death inducer having activity of potentiating anti-cancer agent in cancer having resistance against the anti-cancer agent |
| 05/14/2009 | WO2009060945A1 Combination of anti-angiogenic substance and anti-tumor platinum complex |
| 05/14/2009 | WO2009060865A1 Pharmaceutical composition and method for production of pharmaceutical composition |
| 05/14/2009 | WO2009060835A1 Novel ubiquilin-binding small molecule |
| 05/14/2009 | WO2009060601A1 Agent for treatment of malignant tumor |
| 05/14/2009 | WO2009060493A1 Pharmaceutical composition comprising peroxided oil and cholesterol and uses thereof in medical field |
| 05/14/2009 | WO2009060457A1 Novel synthetic analogs of sphingolipids |
| 05/14/2009 | WO2009060292A2 Smac mimetic compounds as apoptosis inducers |
| 05/14/2009 | WO2009060278A1 Cyclobutyl carboxylic acid derivatives |
| 05/14/2009 | WO2009060215A1 Polyamides |
| 05/14/2009 | WO2009060198A1 Anti-vegf antibody compositions and methods |
| 05/14/2009 | WO2009060197A1 Imidazopyridazines for use as protein kinase inhibitors |
| 05/14/2009 | WO2009060186A1 Sulfonated precursors of thymidine for the treatment of epithelial hyperplasias |
| 05/14/2009 | WO2009060114A1 Inhibitors of enzyme o6-alkylguanine-dna-methyltransferase for cancer treatment |
| 05/14/2009 | WO2009060054A1 Triazole derivatives as scd inhibitors |
| 05/14/2009 | WO2009059984A2 Reversible hydrophobization of antitumor drugs for enhanced first-pass drug uptake |
| 05/14/2009 | WO2009059450A1 Peptide ligand directed drug delivery |
| 05/14/2009 | WO2009059448A1 Styrene-acid derivative and use in manufacturing blood-vessel targeted-agent drugs |
| 05/14/2009 | WO2009059350A1 Anti-microbial polymers and their compositions |
| 05/14/2009 | WO2009040083A3 Use of a peptide as a therapeutic agent |
| 05/14/2009 | WO2009040047A3 Therapeutic uses of ghrelin and combinations with stresscopin |
| 05/14/2009 | WO2009040033A3 Use of a peptide as a therapeutic agent |
| 05/14/2009 | WO2009040019A3 Use of a peptide as a therapeutic agent |
| 05/14/2009 | WO2009039986A3 Use of the peptide asn-asp-asp-cys-glu- leu-cys-val-asn-val-ala-cys-thr-gly-cys-leu alone or in combination with the peptide thr-thr-ser-gln-val- arg-pro-αrg as a therapeutic agent |
| 05/14/2009 | WO2009039337A3 Inhibition of angiogenesis |
| 05/14/2009 | WO2009039199A3 Compositions comprising stat5 sirna and methods of use thereof |
| 05/14/2009 | WO2009039189A3 Compositions comprising stat3 sirna and methods of use thereof |
| 05/14/2009 | WO2009037357A4 Benzimidazole nf- kappab inhibitors |
| 05/14/2009 | WO2009033807A3 Therapeutic uses of b-type natriuretic peptide and human growth hormone 1-43 |
| 05/14/2009 | WO2009033804A3 Use of gamma- endorphin as a therapeutic agent |
| 05/14/2009 | WO2009033803A3 Use of the pentapeptide drlds and gamma-endorphin as therapeutic agents |
| 05/14/2009 | WO2009033799A3 Use of a peptide as a therapeutic agent |
| 05/14/2009 | WO2009033754A8 Use of a peptide as a therapeutic agent |
| 05/14/2009 | WO2009032930A3 Compositions comprising human integrin-linked kinase-sirna and methods of use thereof |
| 05/14/2009 | WO2009031040A3 Compounds with anti-cancer activity |
| 05/14/2009 | WO2009019708A3 Pharmaceutical compositions and methods for the treatment of cancer |
| 05/14/2009 | WO2009018429A3 TREATMENT OF CANCER VIA TARGETING OF IL-13 RECEPTOR-α2 |
| 05/14/2009 | WO2008144507A3 Spirooxindole inhibitors of aurora kinase |
| 05/14/2009 | WO2008137816A3 Tricyclic compounds as matrix metalloproteinase inhibitors |
| 05/14/2009 | WO2008132738A3 Anticancerous polymeric agents |
| 05/14/2009 | WO2008124735A3 Multi-functional polyglutamate drug carriers |
| 05/14/2009 | WO2008117061A3 Tetrahydroisoquinolines as tumour growth inhibitors |
| 05/14/2009 | WO2008088779A3 Solid state forms of 5-azacytidine and processes for preparation thereof |
| 05/14/2009 | WO2008076379A8 Human antibodies to human delta like ligand 4 |
| 05/14/2009 | WO2008041236A3 Composition comprising crustacean gastrolith components, calcium carbonate and its use |
| 05/14/2009 | WO2007059000A3 Modulation of angiogenesis by a-beta peptide fragments |
| 05/14/2009 | US20090124832 Oligoamine compounds and derivatives thereof for cancer therapy |
| 05/14/2009 | US20090124686 Gsk-3 inhibitors |
| 05/14/2009 | US20090124685 Agave syrup extract having anticancer activity |
| 05/14/2009 | US20090124681 Beta-lactone compounds |
| 05/14/2009 | US20090124675 Inhibitors of anti-apoptotic proteins |
| 05/14/2009 | US20090124663 Novel n-phenyl-piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 05/14/2009 | US20090124662 Migrastatin analogs in the treatment of cancer |
| 05/14/2009 | US20090124660 Piperidine Compounds Useful as Malonyl-CoA Decarboxylase Inhibitors |